FTY720, Novel Oral Therapy In Development For MS, Shows Sustained Benefits For The Majority Of Patients After Three Years Of Treatment

The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to new clinical data presented today from an ongoing Phase II study extension1. Results showed that 73% of patients who began the study on FTY720 5 mg remained free from relapses after three years, and 68% of those who began the study on FTY720 1.25 mg remained relapse-free1.

More: continued here

Filed under: Multiple Sclerosis on April 17th, 2008